Personalized neoantigen vaccine shows no cancer recurrence in small phase 1 kidney cancer trial
Evidence stage: Early HumanRegulatory status: Investigational
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
Primary source cited
Last reviewed